The Predictive Value of the Inflammatory Prognostic Index for Detecting No-Reflow in ST-Elevation Myocardial Infarction Patients

Overview

Journal Arq Bras Cardiol

Specialty Cardiology & Vascular Diseases

Date 2024 May 2

PMID 38695475

Authors

Faysal Saylik

Tufan Cinar

Ibrahim Halil Tanboga

Affiliations

Soon will be listed here.

Abstract

Background: No-reflow (NR) is characterized by an acute reduction in coronary flow that is not accompanied by coronary spasm, thrombosis, or dissection. Inflammatory prognostic index (IPI) is a novel marker that was reported to have a prognostic role in cancer patients and is calculated by neutrophil/lymphocyte ratio (NLR) multiplied by C-reactive protein/albumin ratio.

Objective: We aimed to investigate the relationship between IPI and NR in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (pPCI).

Methods: A total of 1541 patients were enrolled in this study (178 with NR and 1363 with reflow). Lasso panelized shrinkage was used for variable selection. A nomogram was created based on IPI for detecting the risk of NR development. Internal validation with Bootstrap resampling was used for model reproducibility. A two-sided p-value <0.05 was accepted as a significance level for statistical analyses.

Results: IPI was higher in patients with NR than in patients with reflow. IPI was non-linearly associated with NR. IPI had a higher discriminative ability than the systemic immune-inflammation index, NLR, and CRP/albumin ratio. Adding IPI to the baseline multivariable logistic regression model improved the discrimination and net-clinical benefit effect of the model for detecting NR patients, and IPI was the most prominent variable in the full model. A nomogram was created based on IPI to predict the risk of NR. Bootstrap internal validation of nomogram showed a good calibration and discrimination ability.

Conclusion: This is the first study that shows the association of IPI with NR in STEMI patients who undergo pPCI.

Citing Articles

Inflammation and No-Reflow: Can it be a Game-Changer?.

Timoteo A Arq Bras Cardiol. 2024; 121(5):e20240119.

PMID: 38896586 PMC: 11164438. DOI: 10.36660/abc.20240119.

References

Wang Z, Ren L, Lei L, Ye H, Peng J . The relationship between neutrophil counts on admission and angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Acta Cardiol. 2016; 71(2):241-6. DOI: 10.2143/AC.71.2.3141856. View

Celik T, Iyisoy A, Kursaklioglu H, Turhan H, Kilic S, Kose S . The impact of admission C-reactive protein levels on the development of poor myocardial perfusion after primary percutaneous intervention in patients with acute myocardial infarction. Coron Artery Dis. 2005; 16(5):293-9. DOI: 10.1097/00019501-200508000-00006. View

Gibson C, Cannon C, Daley W, Dodge Jr J, Alexander Jr B, MARBLE S . TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996; 93(5):879-88. DOI: 10.1161/01.cir.93.5.879. View

Michaels A, Gibson C, Barron H . Microvascular dysfunction in acute myocardial infarction: focus on the roles of platelet and inflammatory mediators in the no-reflow phenomenon. Am J Cardiol. 2000; 85(5A):50B-60B. DOI: 10.1016/s0002-9149(00)00811-0. View

Durante A, Camici P . Novel insights into an "old" phenomenon: the no reflow. Int J Cardiol. 2015; 187:273-80. DOI: 10.1016/j.ijcard.2015.03.359. View

Don B, Kaysen G . Serum albumin: relationship to inflammation and nutrition. Semin Dial. 2005; 17(6):432-7. DOI: 10.1111/j.0894-0959.2004.17603.x. View

Narang R, Ridout D, Nonis C, Kooner J . Serum calcium, phosphorus and albumin levels in relation to the angiographic severity of coronary artery disease. Int J Cardiol. 1997; 60(1):73-9. DOI: 10.1016/s0167-5273(97)02971-9. View

Esenboga K, Kurtul A, Yamanturk Y, Tan T, Tutar D . Systemic immune-inflammation index predicts no-reflow phenomenon after primary percutaneous coronary intervention. Acta Cardiol. 2021; 77(1):59-65. DOI: 10.1080/00015385.2021.1884786. View

Roche M, Rondeau P, Singh N, Tarnus E, Bourdon E . The antioxidant properties of serum albumin. FEBS Lett. 2008; 582(13):1783-7. DOI: 10.1016/j.febslet.2008.04.057. View

10.

Halliwell B . Albumin--an important extracellular antioxidant?. Biochem Pharmacol. 1988; 37(4):569-71. DOI: 10.1016/0006-2952(88)90126-8. View

11.

Kurtul A, Ocek A, Murat S, Yarlioglues M, Demircelik M, Duran M . Serum albumin levels on admission are associated with angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Angiology. 2014; 66(3):278-85. DOI: 10.1177/0003319714526035. View

12.

Askin L, Akturk E . Association between SYNTAX II score and electrocardiographic evidence of no-reflow in patients with ST-segment elevation myocardial infarction. Turk Kardiyol Dern Ars. 2018; 46(6):455-463. DOI: 10.5543/tkda.2018.86132. View

13.

Cinar T, Saylik F, Hayiroglu M, Asal S, Selcuk M, Cicek V . The Association of Serum Uric Acid/Albumin Ratio with No-Reflow in Patients with ST Elevation Myocardial Infarction. Angiology. 2022; 74(4):381-386. DOI: 10.1177/00033197221110700. View

14.

Ibanez B, James S, Agewall S, Antunes M, Bucciarelli-Ducci C, Bueno H . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European.... Eur Heart J. 2017; 39(2):119-177. DOI: 10.1093/eurheartj/ehx393. View

15.

. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med. 1989; 320(10):618-27. DOI: 10.1056/NEJM198903093201002. View

16.

Harrison R, Aggarwal A, Ou F, Klein L, Rumsfeld J, Roe M . Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol. 2012; 111(2):178-84. DOI: 10.1016/j.amjcard.2012.09.015. View

17.

Abbo K, Dooris M, Glazier S, ONeill W, Byrd D, Grines C . Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol. 1995; 75(12):778-82. DOI: 10.1016/s0002-9149(99)80410-x. View

18.

Dirican N, Dirican A, Anar C, Atalay S, Ozturk O, Bircan A . A New Inflammatory Prognostic Index, Based on C-reactive Protein, the Neutrophil to Lymphocyte Ratio and Serum Albumin is Useful for Predicting Prognosis in Non-Small Cell Lung Cancer Cases. Asian Pac J Cancer Prev. 2017; 17(12):5101-5106. PMC: 5454643. DOI: 10.22034/APJCP.2016.17.12.5101. View

19.

Wang J, Zhou Z, Chen Y, Wang C, Zhu X . A risk score for no reflow in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention. Clin Cardiol. 2015; 38(4):208-15. PMC: 6711063. DOI: 10.1002/clc.22376. View

20.

Ohlmann P, Jaquemin L, Morel O, El Behlgiti R, Faure A, Michotey M . Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for ST-elevation myocardial infarction. Am Heart J. 2006; 152(6):1161-7. DOI: 10.1016/j.ahj.2006.07.016. View